Archives
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Another interesting aspect of neutralizing
2023-11-17

Another interesting aspect of neutralizing AP-1 is the inhibition of interactions between AP-1 and Smad proteins, which synergize to activate the TGF-β1-responsive genes involved in hypertrophic growth of the heart muscle and in the development of cardiac fibrosis. Through preventing AP-1 activation
-
Another major problem leading to implant failures is post
2023-11-17

Another major problem leading to implant failures is post-implant infections, majorly due to bacteria adhesion [13,36,37]. A significant decrease in bacterial counts (~65–90%) has been observed in HA and/or CNT-based composites reinforced with 2.5–10 wt% nano Ag [13,38], thus, drawing the conclusion
-
It has been proposed that a PrP pathogenic mechanism
2023-11-17

It has been proposed that a PrP pathogenic mechanism is a toxic gain of function secondary to the misfolding of mutated PrP. However, such a mechanism might not apply to all mutant PrP species, since some mutations had little effect on the stability and folding kinetics of PrP (Swietnicki et al., 19
-
Ac-IETD-AFC br Experimental section br Acknowledgements The
2023-11-17

Experimental section Acknowledgements The authors thank Prof. Yongbing Cao from School of Pharmacy, the Second Military Medical University, for providing the fluconazole-resistant strains of Candida albicans(strain 100 and strain 103). This work was supported by Program for Innovative Research
-
The first evidence in supporting the hypothesis that MAS
2023-11-17

The first evidence in supporting the hypothesis that MAS receptors mediate the effects elicited by AT1 antagonists was provided by Iwai et al. (2012). The authors found that AT1 receptors triggers neointima formation after polyethylene-cuff placement around mouse femoral artery by reducing local ACE
-
br Acknowledgments This work was supported by
2023-11-17

Acknowledgments This work was supported by grants from the “Agence Nationale de la Recherche” ANR-09-CESA-006 program, the Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail (Anses, Project n° 2012-2-077) and the Interdisciplinary Program “Longévité et Viei
-
The expanding catalog of glutamate receptor auxiliary subuni
2023-11-17

The expanding catalog of glutamate receptor auxiliary subunits and associated transmembrane proteins underscores the importance and complexity of the receptor complexes. Whereas the interactions described here specifically control AMPARs, distinct auxiliary subunits, Neto-1/2, modulate neuronal kain
-
br Polymorphic variation ERAP is polymorphic and several sin
2023-11-17

Polymorphic variation ERAP1 is polymorphic and several single nucleotide polymorphisms (SNPs) in its gene that encode amino Ketoprofen changes have been associated with predisposition to a variety of diseases, ranging from viral infections to cancer and autoimmunity (Alvarez-Navarro and Lopez de
-
br Perspective AA LA and
2023-11-17

Perspective AA, LA and other PUFAs and their lipid metabolites play an important role in human diseases. 12/15-LOX which is the metabolic enzyme of them plays an important role in the pathogenesis-related diseases such as atherosclerosis, diabetic nephropathy, neurological diseases and other path
-
br Introduction Nonalcoholic fatty liver disease
2023-11-17

Introduction Nonalcoholic fatty liver disease (NAFLD) is a clinicopathologic spectrum of liver pathologies associated with excessive accumulation of fat in the liver. This spectrum is continuous but can be graded based on pathological features; in increasing severity, these are: bland steatosis,
-
br Detection and possible treatments for
2023-11-17

Detection and possible treatments for prostate cancer PC can be diagnosed, by screening for prostate-specific antigen (PSA) and after diagnosis, treatments may include intense observation, radical prostatectomy, radiation, chemotherapy, hormone therapy or vaccination depending on the type and sta
-
Introduction Diabetic nephropathy is a rapidly growing cause
2023-11-17

Introduction Diabetic nephropathy is a rapidly growing cause of end-stage renal disease [1]. Glomerular, tubular and vascular toxicity resulting from hyperglycemia (glucotoxicity) have been evaluated extensively at the molecular level as contributing factors for diabetic nephropathy [[1], [2], [3]
-
AR-42 HDAC br Results br Discussion Utilizing a proteomic
2023-11-17

Results Discussion Utilizing a proteomic approach, we identified HSP90β as a protein that becomes associated with surface AChR in agrin-stimulated muscle cells. We demonstrate that HSP90β does not interact with the AChR directly; instead, via direct interaction with rapsyn, HSP90β becomes asso
-
br Acknowledgments This work was supported by
2023-11-17

Acknowledgments This work was supported by the R&D Program of the Institutional Research Program of KRICT (SI1701-02), and by the Next generation carbon upcycling project of Ministry of Science and ICT. JSC is kindly grateful to the National Research Council of Science and Technology (NST) for fi
-
Compounds were profiled for their inhibitory activity agains
2023-11-17

Compounds – were profiled for their inhibitory activity against dipeptidyl peptidase-IV Activity and/or Structure Homologues (DASH) [e.g. DPP2, DPP8 and DPP9] and non-DASH [eg. post-proline cleaving enzyme (PPCE), neutral endopeptidase (NEP), aminopeptidase P (APP), aminopeptidase N (APN)] enzymes.
16536 records 260/1103 page Previous Next First page 上5页 256257258259260 下5页 Last page